Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14860386 | 0.74 | GSK3B (0.64) | RPS6KB1CDK2GSK3AGSK3BCDK5 | |
| SCHEMBL4877872 | 0.71 | LMNA (0.48) | GAAGSK3AGSK3BLMNAMEN1 | |
| SCHEMBL4876702 | 0.67 | MAPT (0.49) | GAAGSK3AGSK3BLMNAMEN1 | |
| SCHEMBL3510188 | 0.64 | KMT2A (0.46) | LMNAMEN1KMT2ANPC1RAB9A | |
| SCHEMBL27879709 | 0.64 | NPC1 (0.49) | GAACYP2C9LMNACYP3A4MEN1 | |
| SCHEMBL29090412 | 0.64 | ATM (0.51) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL30547170 | 0.64 | ATM (0.51) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL14880488 | 0.63 | KCNJ1 (0.63) | GAALMNAMEN1KMT2APOLB | |
| SCHEMBL29072235 | 0.63 | ATM (0.50) | GAALMNAMEN1KMT2ANPC1 | |
| SCHEMBL5520026 | 0.63 | ALOX5 (0.47) | LMNANPC1RAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919465-B1 | GSK-3 INHIBITORS | ASD THERAPEUTICS PARTNERS LLC (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20130204238-A1 | COMBINATION THERAPY | FOLLICA, INC (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2552323-A1 | COMBINATION THERAPY | Follica, Inc. (US) | 2013-02-06 | — | — | EP | disclosed |
| WO-2012067631-A1 | BODY SURFACE TREATMENT | FOLLICA, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012067630-A1 | HAIR GROWTH TREATMENT | FOLLICA, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012067632-A1 | SEQUENTIAL BODY SURFACE TREATMENT | FOLLICA, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011123218-A1 | COMBINATION THERAPY | FOLLICA, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110130706-A1 | SEQUENTIAL BODY SURFACE TREATMENT | FOLLICA, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130711-A1 | HAIR GROWTH TREATMENT | FOLLICA, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130748-A1 | BODY SURFACE TREATMENT | FOLLICA, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| EP-1845094-A1 | METHOD OF TUMOR SUPPRESSION AND EVALUATION OF ANTICANCER AGENT BASED ON GSK3 BETA INHIBITORY EFFECT | National University Corporation Kanazawa University (JP) | 2007-10-17 | — | — | EP | disclosed |
| EP-1406883-B1 | 4-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA AND ITS USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH GLYCOGEN-SYNTHASE KINASE-3(GSK3) | ASTRAZENECA AB (SE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007017145-A2 | GSK-3 INHIBITORS | NEUROPHARMA, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
| EP-1749523-A1 | GSK-3 inhibitors | Neuropharma, S.A. (ES) | 2007-02-07 | — | — | EP | disclosed |
| US-7056939-B2 | 4-(4Methoxybenzyl)-n′-(5-nitro1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3 (gsk3) | ASTRAZENECA AB (SE) | 2006-06-06 | — | — | US | disclosed |
| US-20050054698-A1 | 4-(4Methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3(gsk3) | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1406883-A1 | 4-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA AND ITS USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH GLYCOGEN-SYNTHASE KINASE-3(GSK3) | AstraZeneca AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| EP-1406883-A1 | 4-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA AND ITS USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH GLYCOGEN-SYNTHASE KINASE-3(GSK3) | AstraZeneca AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003004478-A1 | 4-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA AND ITS USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH GLYCOGEN-SYNTHASE KINASE-3(GSK3) | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
| WO-2003004478-A1 | 4-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA AND ITS USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH GLYCOGEN-SYNTHASE KINASE-3(GSK3) | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054698-A1 | 4-(4Methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3(gsk3) | GSK3B, GSK3A, PYGL | GAA 179/4885RPS6KB1 207/4885CDK2 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.